Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 9;9(48):28171-28185.
doi: 10.1039/c9ra04518j. eCollection 2019 Sep 3.

Peptidoglycan pathways: there are still more!

Affiliations
Review

Peptidoglycan pathways: there are still more!

Ahmed M Helal et al. RSC Adv. .

Abstract

The discovery of 3rd and 4th generations of currently existing classes of antibiotics has not hindered bacterial resistance, which is escalating at an alarming global level. This review follows WHO recommendations through implementing new criteria for newly discovered antibiotics. These recommendations focus on abandoning old scaffolds and hitting new targets. In light of these recommendations, this review discusses seven bacterial proteins that no commercial antibiotics have targeted yet, alongside their reported chemical scaffolds.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. A diagram showing PG biosynthesis.
Fig. 2
Fig. 2. A schematic illustration of some key steps of PG biosynthesis. Reprinted with permission from Mohammad H., et al., J. Med. Chem., 2017, 2425; copyright: American Chemical Society.
Fig. 3
Fig. 3. A diagram emphasizing the essential role of UppP.
Fig. 4
Fig. 4. The SAR of phenylthiazole antibiotics.
Fig. 5
Fig. 5. Different generations of phenylthiazole antibiotics with their associated antimicrobial, physicochemical and pharmacokinetic properties.
Fig. 6
Fig. 6. The half-lives of different classes of phenylthiazole antibiotics.
None
Ahmed M. Helal
None
Ahmed M. Sayed
None
Mariam Omara
None
Mohamed M. Elsebaei
None
Abdelrahman S. Mayhoub

Similar articles

Cited by

References

    1. Hiramatsu K. Lancet Infect. Dis. 2001;1:147–155. doi: 10.1016/S1473-3099(01)00091-3. - DOI - PubMed
    1. Wilson P. Andrews J. Charlesworth R. Walesby R. Singer M. Farrell D. Robbins M. J. Antimicrob. Chemother. 2003;51:186–188. doi: 10.1093/jac/dkg104. - DOI - PubMed
    1. Jayol A. Nordmann P. Brink A. Villegas M.-V. Dubois V. Poirel L. Antimicrob. Agents Chemother. 2017;61:e01423-17. doi: 10.1128/AAC.01423-17. - DOI - PMC - PubMed
    1. WHO, Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis, World Health Organization, Geneva, 2017, WHO/EMP/IAU/2017.11
    1. Vollmer W. Blanot D. de Pedro M. A. FEMS Microbiol. Rev. 2008;32:149–167. doi: 10.1111/j.1574-6976.2007.00094.x. - DOI - PubMed